tbuckley/cabot-search huggingface dataset:
Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP)
Authors: M. Rivoire, S. Thezenas, C. Rebischung, F. Viret, R. Guimbaud, E. Francois, M. Ducreux, F. Quenet, F. Desseigne, M. Ychou
Journal: Journal of Clinical Oncology (2008)

4075 Background: LVFU combinations with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) have shown to improve outcome of advanced colorectal cancer. However, the standard doses of these regimens applied to patients with initially unresectable LMCRC have shown poor rates of resectability. The aim of this randomized trial was to select the most efficacious experimental intensified chemotherapy arm among high dose (HD) FOLFIRI (Iri 260mg/m²), FOLFOX-7 (Ox 130mg/m²) and FOLFIRINOX (Iri 180mg/m² + Ox 85mg/m²) in patients (pts) with initially unresectable or potentially resectable LMCRC. Methods: Main inclusion criteria: non pretreated potentially resectable LM (class II) or unresectable LM without extra-hepatic metastases except 1 to 3 resectable lung metastases. Pts were randomized to either standard (A/B) or intensified chemotherapy (C/D/E): FOLFIRI (A), FOLFOX-4 (B), FOLFIRI-HD (C), FOLFOX-7 (D), or FOLFIRINOX (E). In arms C/D/E, prophylactic G-CSF was given. Primary endpoint was objective response rate (RR) (RECIST) after Cycle 4. Secondary endpoints were safety, R0 surgical resection, best RR, PFS and OS. A total of 120 pts randomized in a 1:1:2:2:2 ratio were necessary to select an experimental arm (2-stage Fleming design, p0=0.40, p1=0.60, alpha=10%, beta=20%). Results: Between Oct 2004 and Aug 2007, 125 pts from 17 centers were randomized, 122 were eligible and treated: 30 (A+B), 32 (C), 30 (D) and 30 (E). Reasons for unresectability were well balanced: 45% pts had less than 30% of remaining healthy liver, 20% had vascular contact, and 35% were class II. Respectively 20, 12, 23 and 17% had lung metastases in arms (A+B), C, D and E. Grade 3/4 toxicities during the first 4 cycles in Arms (A+B)/C/D/E were respectively: neutropenia (24, 19, 10, 23%) diarrhea (0, 6, 3, 23%), mucositis (0, 3, 0, 7%), vomiting (7, 9, 0, 3%), neurotoxicity (0, 0, 10, 3%). The objective RR after 4 cycles in Arms (A+B)/C/D/E were: 43, 50, 50 and 52%. Conclusions: These results suggest an improvement in early RR for LMCRC with these intensified chemotherapy regimen with acceptable toxicity. Major secondary endpoints such as R0 surgical resection will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pfizer Oncology, sanofi-aventis sanofi-aventis
Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups.
Authors: Sheeba K Thomas, Lei Feng, Kay B Delasalle, Michael Wang, Jatin J Shah, Robert Z Orlowski, Raymond Alexanian, Donna M Weber
Journal: Blood (2009)
Pilot study of early repeated 18F-FDG PET during cycle 1 to predict objective response to chemotherapy in advanced non-small cell lung cancer (NSCLC)
Authors: U. Ricardi, S. Novello, E. Pelosi, M. Giaj Levra, G. Selvaggi, M. Longo, E. Capelletto, B. Crida, S. G. Rapetti, G. V. Scagliotti
Journal: Journal of Clinical Oncology (2008)

8003 Background: FDG-PET already showed to be an early assessment of anticancer treatment effectiveness in different solid tumours after the first cycle of chemotherapy. Aim of this pilot study in patients (pts) with advanced NSCLC was to test if a second 18F-FDG PET repeated two weeks after the start of chemotherapy is predictive of subsequent response and survival. Patients and Methods: Twenty two pts with clinical stage IIIB (n=1) or IV (n=21) NSCLC receiving front line platinum-based chemotherapy within a clinical trial were consecutively and prospectively enrolled. Male/female ratio was 18/4, adenocarcinoma 11, squamous 6, NSCLC-NOS 5. All pts underwent 18F-FDG PET scan at baseline (PET1), 15 days after the beginning (PET2) and at the end of chemotherapy. Assessment of disease by spiral CT scan of the chest and abdomen was performed at baseline and every other cycle. Tumour response was evaluated according to RECIST criteria and analysis of PET scans (including the % change in the standardized uptake values [SUV] between baseline and subsequent FDG PET in the primary tumour (ΔSUV) as well as an overall assessment of all visible lesions) completed and recorded before response evaluation by CT. Results: Pts were dichotomized in two groups (responders and non-responders) based on the overall assessment of FDG PET changes in all visible lesions between PET1 and PET2. Among PET responders, TC scan performed after 2 cycles showed objective response (OR) in 55% of the cases (6/11) while only 1 OR (10%) in non-responders (Fisher exact test, p=0.04). Mean ΔSUV in the primary tumour in PET responders was -40% and in non responders -9%. Overall PET response overestimate CT response in 6/21 cases while underestimate it in 3/21 cases. Adopting different cut-off values for baseline SUV or ΔSUV of the primary lesion no correlation was found with progression-free or overall survival. A non significant trend for improved PFS was found in overall responders (25 weeks) vs non-responders (19 weeks). Data on OS are still immature. Conclusion: This pilot study indicates that in advanced NSCLC early PET restaging during cycle 1 may predicts subsequent OR to CT scan after 2 cycles. This findings are worth of a prospective validation in a larger study. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration AstraZeneca, Bayer, Eli Lilly, Roche, sanofi-aventis
Cisplatin / etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG)
Authors: M. Thomas, H. N. Macha, D. Ukena, M. Hamm, M. Deppermann, M. Semik, D. Riesenbeck, C. Rübe, A. Heinecke
Journal: Journal of Clinical Oncology (2004)

7004 Background: In the neoadjuvant treatment setting of stage III NSCLC the additional impact of hfRT/CT after preoperative CT on resectability and survival is open to conjecture. Methods: In a phase III trial patients [pts] with stage III NSCLC (invasive mediastinal staging obligatory) were stratified (center; stage, IIIA vs IIIB) and then randomized to (arm A) 3 cycles P 55 mg/m2 (d 1+4) / E 100 mg/m2 (d 1–4), followed by hfRT (45 Gy; 2 x 1.5 Gy/d) with concurrent Carboplatin 100 mg/m2 / Vindesin 3 mg (d 1, 8, 15), then surgery and, if no or R1/2-resection, additional hfRT (24 Gy; 2 x 1.5 Gy/d) versus (arm B) 3 cycles of PE followed by surgery and then RT (1.8 Gy/d) with 54 Gy or, if no or R1/2-resection, 68.4 Gy. The primary (secondary) study endpoint was progression free survival [PFS] (survival [S]). With 500 pts. evaluable an improvement of median PFS (S) from 10 to 14 (17 to 23) months [mo]; 3 y.-rate from 8 to 17 (23 to 34) % could be detected. Results: 558 pts. were randomized (10/95–07/03); 32 (6%) were ineligible. On december 1st, 2003 median follow up was 46 mo with outcome data available for 481 pts. Patient characteristics were well balanced between arm A (245 pts.) and arm B (236 pts): male 82%/83%, female 18%/17%; PS 0 86%/87%; PS 1 14%/13%; age 59/59 ys. [median]; stage IIIA 31%/34%; stage IIIB 69%/66%. Whilst the rate of grade 3/4-esophagitis was significantly different between treatment arms (15%/4%, p < 0.001), there was no significant difference for the response rate after induction (52%/47%; p = 0.35), the proportion of patients with complete tumor resection (111/245, 45% /118/236, 50%; p = 0.30), the treatment related mortality rate (5,6%/5,3%), nor for PFS (median, 10/10 mo; 3 y.-rate, 17%/18%; p = 0.37, log-rank) or S (median, 15/17 mo; 3 y.-rate, 24%/23%; p = 0.89, log-rank). Conclusions: In this trial the addition of hfRT/CT to PE prior to planned surgery had no impact on PFS or S but contributed to significantly higher rates of grade 3/4 esophagitis. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly
GW26-e4518 The diversity of BMI and WC on cardiac damage in patients from a cardiac rehabilitation program after acute coronary syndrome
Authors: Lin Xu, Hui Zhao, Jun Ma, Wei Zhu, Hongqiang Lei, Zekun Cai, Yongwang Fan, Xiaoming Huang, Jiangming Huang, Xinyuan Zhao, Yu Shao, Yanzhuo Li, Jian Qiu
Journal: Journal of the American College of Cardiology (2015)
Efficacy of Ursodeoxycholic Acid with Low-Dose Heparin and Prostaglandin E1 in the Prevention of Hepatic Veno-Occlusive Disease After Allogenic Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major.
Authors: Xuedong Wu, Huaying Liu, Yuelin He, Xiaoqin Feng, Geyu Chen, Qingxia Su, Fanyi Meng, Chunfu Li
Journal: Blood (2009)
Financial Hardships Experienced by Cancer Survivors: A Systematic Review
Authors: Cheryl K. Altice, Matthew P. Banegas, Reginald D. Tucker-Seeley, K. Robin Yabroff
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: With rising cancer care costs, including high-priced cancer drugs, financial hardship is increasingly documented among cancer survivors in the United States; research findings have not been synthesized.Methods: We conducted a systematic review of articles published between 1990 and 2015 describing the financial hardship experienced by cancer survivors using PubMed, Embase, Scopus, and CINAHL databases.We categorized measures of financial hardship into: material conditions (eg, out-of-pocket costs, productivity loss, medical debt, or bankruptcy), psychological responses (eg, distress or worry), and coping behaviors (eg, skipped medications).We abstracted findings and conducted a qualitative synthesis.Results: Among 676 studies identified, 45 met the inclusion criteria and were incorporated in the review.The majority of the studies (82%, n ¼ 37) reported financial hardship as a material condition measure; others reported psychological (7%, n ¼ 3) and behavioral measures (16%, n ¼ 7).Financial hardship measures were heterogeneous within each broad category, and the prevalence of financial hardship varied by the measure used and population studied.Mean annual productivity loss ranged from $380 to $8236, 12% to 62% of survivors reported being in debt because of their treatment, 47% to 49% of survivors reported experiencing some form of financial distress, and 4% to 45% of survivors did not adhere to recommended prescription medication because of cost.Conclusions: Financial hardship is common among cancer survivors, although we found substantial heterogeneity in its prevalence.Our findings highlight the need for consistent use of definitions, terms, and measures to determine the best intervention targets and inform intervention development in order to prevent and minimize the impact of financial hardship experienced by cancer survivors.
Pyrrolo[1,2-B][1,2,5] benzodiazepines (PBTDs) Compounds Induce Apoptosis in Chronic Myeloid Leukaemia Cells from Patients at Onset, Imatinib and Second Generation TK Inhibitors (Dasatinib, Nilotinib) Resistant.
Authors: Elisabetta Abruzzese, Gabriella Marfe’, Carla Di Stefano, Malgorzata M. Trawinska, Matteo A. Russo, Romano Silvestri, Giovanni Del Poeta, Giovanni Martinelli, Simona Soverini, Paolo de Fabritiis, Sergio Amadori, Paola Sinibaldi Salimei
Journal: Blood (2006)
Gastric adenocarcinoma treated with radiation with or without epirubicin-based chemotherapy: Evaluation of radiation-induced liver disease.
Authors: J. D. Schoenfeld, H. J. Mamon, L. S. Blaszkowsky, P. C. Enzinger, J. Y. Wo, J. N. Allen, R. C. Wadlow, D. P. Ryan, T. S. Hong
Journal: Journal of Clinical Oncology (2011)

110 Background: Anthracycline chemotherapy has been associated with radiation-induced liver disease (RILD). We sought to compare the incidence of liver toxicity among patients with gastric adenocarcinoma treated with radiotherapy (RT) with or without epirubicin-based chemotherapy. Methods: We performed a retrospective analysis of 94 patients with gastric adenocarcinoma treated at Massachusetts General Hospital since November 2005 and the Dana-Farber Cancer Institute since August 1998. All patients underwent definitive surgery and RT (median dose 45 Gray) with a minimum follow up of 6 months. Primary endpoints were development of ascites, radiographic liver change and elevations in liver function tests (LFTs), including alkaline phosphatase (ALP), aspartate transaminase (AST) and alanine transaminase (ALT). Results: In total, 34 patients received epirubicin-based chemotherapy including 9 perioperatively (6 with oxaliplatin and capecitabine [EOX]; 2 with cisplatin and 5-flourouracil [ECF]; 1 with oxaliplatin and 5-flourouracil [EOF]) and 25 postoperatively (2 EOX; 22 ECF; 1 combination). Seven patients were treated with neoadjuvant RT; 87 received adjuvant RT a median of 88 days after surgery (interquartile range 73-108 days). Twenty-one patients developed ascites within 6 months of completing RT, all but one of whom developed peritoneal carcinomatosis or metastatic disease. Among 57 patients that did not develop metastases, maximum elevations in LFTs were similar in patients that received epirubicin-based chemotherapy compared to those who did not (ALP/AST/ALT 150/44/50 vs. 142/41/44, p=0.25/0.36/0.14, respectively), as were rates of radiographic liver change (22% vs. 13%, p=0.44). Conclusions: Epirubicin-based chemotherapy does not significantly increase the risk of RILD in a recent cohort of patients treated with modern RT techniques and dose-constraints. In this setting, treatment of gastric adenocarcinoma with RT and either pre- or postoperative chemotherapy is well tolerated with low rates of liver toxicities. Development of liver toxicity, particularly ascites, within six months of RT may be a harbinger of metastatic disease. No significant financial relationships to disclose.
GW26-e1584 Diabetic related TXNIP-Wnt pathway aberration in cardiac endothelium contributes to the myocardial infarction intolerance
Authors: Mingzhi Shen, Guodong Yang, Danna Bai, Chao Zeng, Na Li, Congye Li, Rongqing Zhang, Zhenhong Fu, Tao Yin, Lijun Yuan, Haichang Wang
Journal: Journal of the American College of Cardiology (2015)
Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission.
Authors: Farhad Ravandi, Jean-Pierre Issa, Stefan Faderl, Guillermo Garcia-Manero, Mary Hood, Jeffrey Jorgensen, Ming Lee, Susan O’Brien, Elihu Estey, Gautam Borthakur, Alessandra Ferrajoli, Srdan Verstovsek, Jorge Cortes, Hagop Kantarjian
Journal: Blood (2007)
Increased of overall survival (OS) and malignancies (K) during tyrosine kinase inhibitors (TKI) in a real life cohort of patients (pts) with a chronic myeloid leukemia (CML).
Authors: M. Gourin, P. Turlure, N. Gachard, S. Girault, M. Touati, J. Abraham, C. Philippon, J. Feuillard, D. Bordessoule
Journal: Journal of Clinical Oncology (2010)

6602 Background: Management of CML has been transformed by targeted therapies like TKI. It has been described in clinical trial that an increased OS of pts giving hope but also opportunity to observe late effects of TKI treatment (Tt) as an increased occur of K. Our objective was to evaluate in a real life cohort of CML pts the impact of TKI on OS and to report new diagnosed K occurring during Tt. Methods: We conducted a retrospective, observational study from the CML database including all consecutive pts with CML into a French regional network. Included criteria were cytogenetic (Cg) or molecular (MB) proved CML. Clinical and biological data, Tt response and outcome including other K were collected and statistically analyzed. Results: We identified 176 pts with CML diagnosed since 1978, SR 1.2, median age 59 (22-84), regional incidence 1.08 vs 1 in France. At diagnosis, pts were in CML-CP 92% (n = 162), CML-AP 5.7% (n = 10), CML-BC 0.6% (n = 1), missing (ND) 1.7% (n = 3). Sokal < 0.8 for 61% (n = 108), 0.8-1.2 for 24% (n = 42), > 1.2 for 11% (n = 19), ND for 4% (n = 7). t(9,22) or Bcr-Abl expressing in MB was 100% with another Cg abnormality in 8%.Tt was non TKI 28% (n = 49), TKIs for 72% (127/176) with 54% (n = 68) in first line, 20% (n = 26) second line and 26% (n = 33) third line or more. In TKI cohort: RCC at 6, 12 and 24 months (m) were respectively 57%, 66%, 83% and MMR/CMR at 6, 12 and 24 m were 14%, 23%, 37%. K occurred during TKI in 12 pts (9.6%), SR 1.4, median age 76 (59-86), median follow up of CML 40.5 m (28-137), median duration TKI: 37 m (26-77). Histologic type of K : 3 prostate, 2 colon, 1 breast, 1 pancreas, 1 lung, 1 parotid, 1 melanoma, 1 renal and 1 bladder. 92% (n = 11) were treated for K, 75% (n = 9) still alive with TKI. Median OS of pts never receiving TKI: 4 y, receiving TKI in second line or more: 18 y, TKI in first line: not reached (p < 0.0001). Conclusions: In real life,TKI Tt with monitored response according to the guidelineshad improved median OS of pts non included in clinical trial, even if they already received several lines of Tt. The occurence of K diagnosed during TKI in our study was 9.6% vs. 4.07% reported in another study (Verma ASH 2008). The older median age in our series (76 y vs. 67 y) may explain the higher rate of K. No significant financial relationships to disclose.
Gunmen and Ice Cream Cones: Harm to Autonomy and Harm to Persons
Authors: J. S. Blumenthal-Barby, Peter A. Ubel
Journal: The American Journal of Bioethics (2016)

"Gunmen and Ice Cream Cones: Harm to Autonomy and Harm to Persons." The American Journal of Bioethics, 16(11), pp. 13–14
Incidence and Outcome of Chronic Myeloproliferative Disorders: A Population-Based Study from a Cancer Registry in Northern Italy.
Authors: Alessia Bari, Raffaella Marcheselli, Ivan Rashid, Goretta Bonacorsi, Orsola Bonanno, Paola Temperani, Giovanna Leonardi, Massimo Federico, Stefano Sacchi
Journal: Blood (2007)
Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
Authors: Thomas Prebet, Steven D. Gore, Benjamin Esterni, Raphael Itzykson, Sylvain Thepot, C.L. Beach, Pierre Fenaux, Norbert Vey
Journal: Blood (2010)
EARLY DIAGNOSIS OF CERVICAL CANCER.
Authors: C BECLERE
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Цитокіновий статус у дітей із хронічною гастродуоденальною патологією
Authors: T.V. Sorokman, S.V. Sokolnyk, O.-M.V. Popelyuk
Journal: GASTROENTEROLOGY (2016)

Актуальність. Частота захворювань шлунка та дванадцятипалої кишки у дітей має тенденцію до невпинного зростання, а сама патологія характеризується групою особливостей, що відсутні у дорослих. Мета: виявити особливості цитокінового профілю сироватки крові у дітей із хронічною гастродуоденальною патологією (ХГДП). Матеріал та методи. Основну клінічну групу становили 54 дитини у віці 8–18 років із ХГДП. Групу порівняння становили 24 практично здорові дитини, порівнянні за віком та статтю з основною клінічною групою. Результати. У 88,9 % дітей із ХГДП виявлено підвищення інтерлейкіну-4 (IL-4) щодо показників у дітей групи порівняння. При приєднанні H.pylori вміст IL‑4 знижувався. Концентрація фактора некрозу пухлини альфа (TNF-α) вірогідно не відрізнялася від такої у дітей групи порівняння при всіх варіантах інфікування, але дещо вищі його значення були при паразитозах. Найвищий показник IL‑4 зареєстрований при виразковому ураженні слизової оболонки шлунка та дванадцятипалої кишки. У цих же пацієнтів відзначено максимально високий рівень TNF-α. Висновок. У дітей із виразковим ураженням слизової оболонки, підвищеною кислотоутворюючою функцією шлунка, значною поширеністю ураження (пангастрит) виявлені вірогідно вищі значення ІЛ‑4 та TNF-α.
Human CD34+Cells Mobilized by AMD3100 Demonstrate Enhanced NOD/SCID Repopulating Function Compared to CD34+ Cells Mobilized by Granulocyte Colony Stimulating Factor.
Authors: David A. Hess, Louisa Wirthlin, Timothy P. Craft, Jesper Bonde, Ryan W. Lahey, Sarah A. Hohm, Phillip E. Herrbrich, John F. DiPersio, Steven M. Devine, Jan A. Nolta
Journal: Blood (2005)
Abstract IA22: Modeling and targeting the tumor microenvironment of pancreatic cancer
Authors: Dieter Saur
Journal: Cancer Research (2016)

Abstract Maintenance and drug resistance of pancreatic ductal adenocarcioma (PDAC) depends on cancer cell intrinsic mechanisms and a stroma that supports tumor growth. Mouse models of human PDAC have provided important insights into the evolution of this highly lethal tumor, but there are no models that allow secondary genetic manipulation of autochthonous tumors, the tumor microenvironment or the metastatic host niche once the tumor has formed. We generated an inducible dual-recombinase system by combining Flp/frt and Cre/loxP. This novel PDAC model permits spatial and temporal control of gene expression enabling unbiased genetic approaches to study the role of tumor cell-autonomous and non-autonomous functions in endogenous cancers. This tool provides unparalleled access to the native biology of cancer cells and their hosting stroma, and rigorous genetic validation of candidate therapeutic targets. We performed tumor cell-autonomous and non-autonomous targeting, uncovered hallmarks of human multistep carcinogenesis, validated genetic tumor therapy, and showed that mast cells in the tumor microenvironment, which had been thought to be key oncogenic players, are in fact dispensable for tumor formation. Citation Format: Dieter Saur. Modeling and targeting the tumor microenvironment of pancreatic cancer. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr IA22.
Charles Roger Heyden Green
Authors: Stephen Oliver
Journal: BMJ (2016)

After his time at Cambridge and the Middlesex Hospital, Charles Roger Heyden Green acted as a house officer at St Andrew’s Hospital in Dollis Hill, north London, and in the casualty department of the Middlesex Hospital. He joined the Royal Army Medical Corps in September 1945, serving as a lieutenant in Egypt and Palestine. He was then posted to Bury St Edmunds, where he subsequently joined …
Intracellular HMGB1 Transactivates the Human IL1B Gene Promoter through Association with an ETS Transcription Factor PU.1.
Authors: Junichi Tsukada, Fumihiko Mouri, Takamitsu Mizobe, Takehiro Higashi, Hiroto Izumi, Kimitoshi Kohno, Yoshiya Tanaka
Journal: Blood (2006)